BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
- The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene therapy, valoctocogene roxaparvovec.
- With today's validation, the application review can now commence. A CHMP opinion is anticipated in the first half of 2022.
- BioMarin resubmitted the European marketing application in June.
- In the U.S., BioMarin intends to submit two-year follow-up safety and efficacy data on all study participants from the Phase 3 GENEr8-1 study to support the benefit/risk assessment of valoctocogene roxaparvovec, as previously requested by the FDA.
- BioMarin targets an application resubmission in Q2 of 2022, assuming favorable study results, followed by an expected six-month review by the FDA.
- Price Action: BMRN shares are down 1.21% at $78.72 during the market session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs gene therapy Hemophilia ABiotech News Health Care FDA General
